Background Aberrant somatic genomic alteration including copy number amplification is a
hallmark of cancer genomes. We previously profiled genomic landscapes of prostate cancer …

Simple Summary Prostate cancer (PCa) has the highest incidence of malignant tumors and
is the second-ranked tumor-causing death of men. GATA binding protein 5 (GATA5) belongs …

Effective treatment for metastatic prostate cancer is critically needed. The present study was
aimed at identifying metastasis-driving genes as potential targets for therapy (oncotargets) …

GATA-2, a member of the GATA family of transcription factors, is involved in androgen
receptor (AR) signaling, however, little is known regarding its role in prostate cancer. Here …

GATA2 is a pioneering transcription factor governing androgen receptor expression and
signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in …

Genome-wide association studies (GWAS) have identified rs11672691 at 19q13 associated
with aggressive prostate cancer (PCa). Here, we independently confirmed the finding in a …

Castration-resistant prostate cancer (CRPC) remains highly lethal and in need of novel,
actionable therapeutic targets. The pioneer factor GATA2 is a significant prostate cancer …

Prostate cancer is the most diagnosed non-skin cancer in the US and kills approximately
27,000 men per year in the US. Additional genetic mouse models are needed that …

Background GATA3 functions as a tumor suppressor and has been observed in multiple
types of cancer, but the effects and mechanisms of GATA3 in osteosarcoma (OS) are not yet …

Castration-resistant prostate cancer (CRPC) nearly inevitably develops after long-term
treatment with androgen deprivation therapy (ADT), leading to significant mortality …